< Back to the team

J. Gardette

Founder & President

Serial Entrepreneur in Healthcare & Digital Health.

He has founded 10+ companies in his career,  with successful exits: 6 of these being sold to large lifescience companies such as Bard, Baxter or Nipro Healthcare in various areas from Dialysis, Drug Delivery Devices or Cardiac Valves.

Former funder and principal shareholder of Biocorp, now sold to Novo Nordisk for 154M€

Pioneer in innovative medicale devices,  and currently listed on Alternext Paris.

Linkedin-in

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page